Switch theme
Sign up to access all valuation multiples
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
2002
368
LTM Revenue $211M
Last FY EBITDA -$32.5M
-$73.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vanda Pharmaceuticals has a last 12-month revenue (LTM) of $211M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Vanda Pharmaceuticals achieved revenue of $199M and an EBITDA of -$32.5M.
Vanda Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vanda Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $211M | XXX | $199M | XXX | XXX | XXX |
| Gross Profit | $197M | XXX | $187M | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | 94% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$32.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -16% | XXX | XXX | XXX |
| EBIT | -$69.9M | XXX | -$40.7M | XXX | XXX | XXX |
| EBIT Margin | -33% | XXX | -20% | XXX | XXX | XXX |
| Net Profit | -$47.5M | XXX | -$18.9M | XXX | XXX | XXX |
| Net Margin | -23% | XXX | -10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Vanda Pharmaceuticals's stock price is $4.
Vanda Pharmaceuticals has current market cap of $256M, and EV of -$73.4M.
See Vanda Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$73.4M | $256M | XXX | XXX | XXX | XXX | $-0.81 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Vanda Pharmaceuticals has market cap of $256M and EV of -$73.4M.
Vanda Pharmaceuticals's trades at -0.4x EV/Revenue multiple, and 2.3x EV/EBITDA.
Equity research analysts estimate Vanda Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vanda Pharmaceuticals has a P/E ratio of -5.4x.
See valuation multiples for Vanda Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $256M | XXX | $256M | XXX | XXX | XXX |
| EV (current) | -$73.4M | XXX | -$73.4M | XXX | XXX | XXX |
| EV/Revenue | -0.3x | XXX | -0.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBIT | 1.1x | XXX | 1.8x | XXX | XXX | XXX |
| EV/Gross Profit | -0.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.4x | XXX | -13.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 4.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVanda Pharmaceuticals's last 12 month revenue growth is 26%
Vanda Pharmaceuticals's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.6M for the same period.
Vanda Pharmaceuticals's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vanda Pharmaceuticals's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Vanda Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 26% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -16% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 20% | XXX | 9% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 115% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vanda Pharmaceuticals acquired XXX companies to date.
Last acquisition by Vanda Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Vanda Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Vanda Pharmaceuticals founded? | Vanda Pharmaceuticals was founded in 2002. |
| Where is Vanda Pharmaceuticals headquartered? | Vanda Pharmaceuticals is headquartered in United States of America. |
| How many employees does Vanda Pharmaceuticals have? | As of today, Vanda Pharmaceuticals has 368 employees. |
| Who is the CEO of Vanda Pharmaceuticals? | Vanda Pharmaceuticals's CEO is Dr. Mihael Hristos Polymeropoulos,M.D.. |
| Is Vanda Pharmaceuticals publicy listed? | Yes, Vanda Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Vanda Pharmaceuticals? | Vanda Pharmaceuticals trades under VNDA ticker. |
| When did Vanda Pharmaceuticals go public? | Vanda Pharmaceuticals went public in 2006. |
| Who are competitors of Vanda Pharmaceuticals? | Similar companies to Vanda Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Vanda Pharmaceuticals? | Vanda Pharmaceuticals's current market cap is $256M |
| What is the current revenue of Vanda Pharmaceuticals? | Vanda Pharmaceuticals's last 12 months revenue is $211M. |
| What is the current revenue growth of Vanda Pharmaceuticals? | Vanda Pharmaceuticals revenue growth (NTM/LTM) is 26%. |
| What is the current EV/Revenue multiple of Vanda Pharmaceuticals? | Current revenue multiple of Vanda Pharmaceuticals is -0.3x. |
| Is Vanda Pharmaceuticals profitable? | Yes, Vanda Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
